Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Posted: December 7, 2020 at 4:58 pm

myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders

Read more here:
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Related Posts